Cargando…

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

The DNA damage response kinase ATR may be a useful cancer therapeutic target. ATR inhibition synergizes with loss of ERCC1, ATM, XRCC1 and DNA damaging chemotherapy agents. Clinical trials have begun using ATR inhibitors in combination with cisplatin. Here we report the first synthetic lethality scr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohni, Kareem N., Thompson, Petria S., Luzwick, Jessica W., Glick, Gloria G., Pendleton, Christopher S., Lehmann, Brian D., Pietenpol, Jennifer A., Cortez, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428765/ https://www.ncbi.nlm.nih.gov/pubmed/25965342 http://dx.doi.org/10.1371/journal.pone.0125482

Ejemplares similares

Functional Analysis of the Replication Fork Proteome Identifies BET Proteins as PCNA Regulators
por: Wessel, Sarah R., et al.
Publicado: (2019)

Protection of abasic sites during DNA replication by a stable thiazolidine protein-DNA crosslink
por: Thompson, Petria S., et al.
Publicado: (2019)

Mutation of Serine 1333 in the ATR HEAT Repeats Creates a Hyperactive Kinase
por: Luzwick, Jessica W., et al.
Publicado: (2014)

FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer
por: Menon, Shruti, et al.
Publicado: (2023)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2015)

Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
por: Sanjiv, Kumar, et al.
Publicado: (2016)

ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies
por: Botrugno, Oronza A., et al.
Publicado: (2019)

A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers
por: Hocke, Sandra, et al.
Publicado: (2016)

Herpes Simplex Virus Type 1 Single Strand DNA Binding Protein and Helicase/Primase Complex Disable Cellular ATR Signaling
por: Mohni, Kareem N., et al.
Publicado: (2013)

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016)

Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells
por: Sun, Zhe, et al.
Publicado: (2022)

DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)

Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition
por: Wang, Chao, et al.
Publicado: (2018)

Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015)

Tissue regenerative delays and synthetic lethality in adult mice upon combined deletion of ATR and p53
por: Ruzankina, Yaroslava, et al.
Publicado: (2009)

ATR activation is regulated by dimerization of ATR activating proteins
por: Thada, Vaughn, et al.
Publicado: (2021)

Genome-wide CRISPR synthetic lethality screen identifies a role for the ADP-ribosyltransferase PARP14 in DNA replication dynamics controlled by ATR
por: Dhoonmoon, Ashna, et al.
Publicado: (2020)

The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin
por: Su, Haochen, et al.
Publicado: (2023)

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
por: Azorsa, David O, et al.
Publicado: (2009)

Evolving DNA repair synthetic lethality targets in cancer
por: Kulkarni, Sanat, et al.
Publicado: (2022)

Genetic landscape of T cells identifies synthetic lethality for T-ALL
por: O’Meara, Connor P., et al.
Publicado: (2021)

Synthetic Lethality Screening Identifies FDA-Approved Drugs that Overcome ATP7B-Mediated Tolerance of Tumor Cells to Cisplatin
por: Mariniello, Marta, et al.
Publicado: (2020)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer
por: Bhoir, Siddhant, et al.
Publicado: (2023)

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors
por: Folk, Watson P., et al.
Publicado: (2021)

Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase Inhibition Is Synthetically Lethal in XRCC1 Deficient Ovarian Cancer Cells
por: Sultana, Rebeka, et al.
Publicado: (2013)

Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer
por: Du, Wushuang, et al.
Publicado: (2021)

Rapid-SL identifies synthetic lethal sets with an arbitrary cardinality
por: Dehghan Manshadi, Mehdi, et al.
Publicado: (2022)

Synthetically Lethal Nanoparticles for Treatment of Endometrial Cancer
por: Ebeid, Kareem, et al.
Publicado: (2017)

VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response
por: Liang, Xiao, et al.
Publicado: (2019)

IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin
por: O'Flanagan, Ciara H., et al.
Publicado: (2016)

Synthetic lethality: emerging targets and opportunities in melanoma
por: Thompson, Nicola, et al.
Publicado: (2017)

Modeling synthetic lethality
por: Le Meur, Nolwenn, et al.
Publicado: (2008)

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications
por: Spalato-Ceruso, M, et al.
Publicado: (2023)

RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells
por: Bauer, Joshua A, et al.
Publicado: (2010)

Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD
por: Hewitt, Graeme, et al.
Publicado: (2021)

Identifying collateral and synthetic lethal vulnerabilities within the DNA-damage response
por: Pinoli, Pietro, et al.
Publicado: (2021)

ATR mediates cisplatin resistance in a p53 genotype-specific manner
por: Sangster-Guity, N, et al.
Publicado: (2011)

Synthetic Lethality in Ovarian Cancer
por: Chandrasekaran, Akshaya, et al.
Publicado: (2021)

Mechanism of RBBP8‐mediated homologous recombination repair in gastric cancer synthetic lethal
por: Yu, Yang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nq01lto73vbf0ispk1cm9jokpb